AKORN INC
AKORN INC (AKRX): 6 pipeline candidates · ~63 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
63.3 months
D/E -13.73 · 0% dilution
Lead: Approved
6 candidates
N/A
N/A
A transparent, data-derived signal for AKORN INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$83.9M
Quarterly Burn
$9.6M
Runway
63.3 mo
Revenue
$120.3M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (6 candidates)
| Drug | Phase |
|---|---|
| ak-fluor | Approved |
| cosopt pf | Approved |
| doptelet | Approved |
| palonosetron | Approved |
| sodium chloride | Approved |
| zioptan | Approved |
Frequently asked questions
How many drug candidates are in AKORN INC's pipeline?
AKORN INC (AKRX) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is AKORN INC's lead drug candidate?
AKORN INC's most advanced tracked candidate is ak-fluor (Approved) for diagnostic fluorescein angiography or angioscopy of the retina and iris vasculature.
What is AKORN INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, AKORN INC has approximately 63.3 months of cash runway.
Get the full picture on AKORN INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.